// App-Quantinova.ai

e14587 : Phase II clinical trial using novel peptide vaccine cocktail as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.

Researchers

Presenter

  • Hiroki Yamaue

Principal Investigators

  • Motoki Miyazawa

  • Masahiro Katsuda

  • Hiroyuki Maguchi

  • Hiroshi Ishii

  • Kenji Yamao

  • Manabu Kawai

  • Seiko Hirono

  • Ken-Ichi Okada

  • Atsushi Shimizu

  • Yuji Kitahata

Medical Centers

  • Second Department of Surgery, Wakayama Medical University School of Medicine, Wakayama, Japan

  • Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan

  • National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

  • Aichi Cancer Center Hospital, Nagoya, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Pancreatic cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Peptide vaccine

  • Gemcitabine

Outcome

  • Negative

Study Design

  • Fixed Dose

  • Single Arm

Phase

  • II

Study Id's

  • UMIN000007991

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved